Clincosm LogoSign in Get a demo

Recurrent Diffuse Large B-Cell Lymphoma

Showing 26 - 46 of 46
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent

Recruiting
  • Clonal Cytopenia of Undetermined Significance
  • +6 more
  • Ascorbic Acid
  • +12 more
  • Scottsdale, Arizona
  • +4 more
May 26, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +11 more
  • Atlanta, Georgia
  • +1 more
Apr 18, 2022

Recurrent DLBCL, Recurrent Mantle Cell Lymphoma, Refractory DLBCL Trial in Duarte (Autologous

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Mar 28, 2022

AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I DLBCL Trial in United States

Completed
Has Results
  • AIDS-Related Plasmablastic Lymphoma
  • +15 more
  • Montgomery, Alabama
  • +34 more
Feb 23, 2022

Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Mar 8, 2022

AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection Trial (Axicabtagene Ciloleucel,

Not yet recruiting
  • AIDS-Related Diffuse Large B-cell Lymphoma
  • +14 more
  • Axicabtagene Ciloleucel
  • +2 more
  • (no location specified)
Feb 15, 2022

Mantle Cell Lymphoma, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Houston (procedure, drug, biological)

Completed
  • Mantle Cell Lymphoma
  • +6 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 18, 2022

CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in Buffalo (drug, other, biological)

Active, not recruiting
Has Results
  • CD20 Positive
  • +6 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 11, 2021

Hematopoietic Cell Transplantation Recipient, Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma Trial in Columbus

Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +11 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 29, 2021

DLBCL Unclassifiable, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial in Duarte,

Recruiting
  • Diffuse Large B-Cell Lymphoma Unclassifiable
  • +6 more
  • Duarte, California
  • +1 more
Oct 1, 2021

Recurrent DLBCL, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Bethesda, Rochester, Omaha

Completed
Has Results
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • Ruxolitinib Phosphate
  • Bethesda, Maryland
  • +2 more
Jul 7, 2021

High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in New Brunswick

Withdrawn
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • +6 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jun 12, 2020

Recurrent DLBCL, Refractory DLBCL Trial in Omaha (Ibrutinib, Laboratory Biomarker Analysis, PI3K-delta Inhibitor TGR-1202)

Completed
Has Results
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Omaha, Nebraska
    University of Nebraska Medical Center
Feb 12, 2020

CD19 Positive, Mantle Cell Lymphoma, Recurrent DLBCL Trial in Houston (procedure, drug, biological)

Withdrawn
  • CD19 Positive
  • +6 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2020

Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma Trial in Houston

Not yet recruiting
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +6 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 6, 2020

Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia Trial in

Completed
Has Results
  • Aggressive Non-Hodgkin Lymphoma
  • +20 more
  • Atorvastatin Calcium
  • +7 more
  • Denver, Colorado
  • +1 more
Dec 26, 2019

CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma Trial in Houston (procedure, biological, drug)

Completed
  • CD20 Positive
  • +6 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
May 30, 2019

Recurrent CNS Lymphoma, Recurrent DLBCL, Refractory CNS Lymphoma Trial in Nashville (Nivolumab, Rituximab, Lenalidomide)

Terminated
  • Recurrent Central Nervous System Lymphoma
  • +3 more
  • Nivolumab
  • +2 more
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Apr 23, 2019

Recurrent DLBCL, Refractory DLBCL Trial in Duarte, New York (radiation, drug, procedure, biological)

Terminated
Has Results
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • 90-Yttrium Ibritumomab tiuxetan
  • +6 more
  • Duarte, California
  • +1 more
Feb 12, 2018

CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in New York (drug, other, biological)

Completed
  • CD20 Positive
  • +2 more
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Jan 25, 2018